Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Farmaceutica RemediaLTS:0M8I 58 Cyclically Adjusted PS Ratio is 0.15 as of Aug. 12, 2026, which is at its 10-year median of 0.15. GuruFocus rates LTS:0M8I with a GF Score™ of 58/100 and a GF Value™ of lei0.23. The stock has 8 warning signs investors should review. Among 89 Medical Distribution companies, Farmaceutica Remedia ranks better than 78.65% on this metric.
The historical rank and industry rank for Farmaceutica Remedia's Cyclically Adjusted PS Ratio or its related term are showing as below:
LTS:0M8I'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.11 Med: 0.15 Max: 0.22
Current: 0.15
During the past years, Farmaceutica Remedia's highest Cyclically Adjusted PS Ratio was 0.22. The lowest was 0.11. And the median was 0.15.
LTS:0M8I's Cyclically Adjusted PS Ratio is ranked better than 78.65% of 89
companies
in the Medical Distribution industry
Industry Median: 0.35
vs LTS:0M8I: 0.15
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Farmaceutica Remedia's adjusted revenue per share data for the three months ended in Mar. 2026 was lei1.796. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is lei1.70 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Farmaceutica Remedia (LTS:0M8I) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Farmaceutica Remedia Cyclically Adjusted PS Ratio Related Terms
Farmaceutica Remedia Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Farmaceutica Remedia's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Farmaceutica Remedia Cyclically Adjusted PS Ratio Chart
LTS:0M8I vs MCK, COR, CAH: Cyclically Adjusted PS Ratio Comparison
For the Medical Distribution subindustry, Farmaceutica Remedia's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Farmaceutica Remedia Cyclically Adjusted PS Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Farmaceutica Remedia's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Farmaceutica Remedia's Cyclically Adjusted PS Ratio falls into.
Farmaceutica Remedia Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 0.15 mean?
Farmaceutica Remedia (LTS:0M8I) has a Cyclically Adjusted PS Ratio of 0.15 as of Aug. 12, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Farmaceutica Remedia and its competitors. This is near median its historical median of 0.15. Over the past decade, Farmaceutica Remedia's Cyclically Adjusted PS Ratio has ranged from 0.11 to 0.22. According to the industry distribution chart, Farmaceutica Remedia ranks #19 out of 89 companies in the Medical Distribution industry, placing it in the top 21.3%.
Is Farmaceutica Remedia's Cyclically Adjusted PS Ratio too high?
Farmaceutica Remedia's current Cyclically Adjusted PS Ratio of 0.15 is near median its 10-year median of 0.15. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 0.22. The Medical Distribution industry median Cyclically Adjusted PS Ratio is 0.35. Farmaceutica Remedia's value of 0.15 is 57.1% below this industry median. Based on the distribution chart, Farmaceutica Remedia ranks #19 out of 89 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Farmaceutica Remedia has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Farmaceutica Remedia's Cyclically Adjusted PS Ratio compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Farmaceutica Remedia ranks #19 out of 89 companies for Cyclically Adjusted PS Ratio. This places Farmaceutica Remedia in the top 21% of its industry — outperforming the majority of peers. The industry median Cyclically Adjusted PS Ratio is 0.35. Farmaceutica Remedia's value of 0.15 is 57.1% below this benchmark. Historically, Farmaceutica Remedia's own Cyclically Adjusted PS Ratio has ranged from 0.11 to 0.22 over the past decade. While the company's 10-year median is 0.15 vs. the industry median of 0.35, Farmaceutica Remedia has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Distribution company?
The median Cyclically Adjusted PS Ratio among Medical Distribution companies is 0.35, based on 89 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Farmaceutica Remedia's current Cyclically Adjusted PS Ratio of 0.15 is 57.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Farmaceutica Remedia and its competitors. For the Medical Distribution industry, the median Cyclically Adjusted PS Ratio is 0.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Farmaceutica Remedia's current Cyclically Adjusted PS Ratio is 0.15, which is near median its own 10-year median of 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmaceutica Remedia stock overvalued right now?
Farmaceutica Remedia (LTS:0M8I) has a current Cyclically Adjusted PS Ratio of 0.15. The stock's GF Value™ is lei0.23, compared to a current price of lei0.25 — trading 8.7% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 0.15, which is near median its 10-year median of 0.15 and 57.1% below the Medical Distribution industry median of 0.35. Farmaceutica Remedia's overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Farmaceutica Remedia (LTS:0M8I), the current Cyclically Adjusted PS Ratio is 0.15 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Farmaceutica Remedia (LTS:0M8I) Overvalued in 2026?
Based on GuruFocus' analysis, Farmaceutica Remedia stock appears to be overvalued.
The current stock price of lei0.25 is trading 8.7% above its estimated GF Value™ of lei0.23.
Key valuation signals for LTS:0M8I:
Cyclically Adjusted PS Ratio: 0.15 (near median its 10-year median of 0.15)
GF Value™: lei0.23 vs. price of lei0.25 (8.7% above fair value)
Industry Position: 57.1% below the Medical Distribution median (#19 of 89)
No single metric tells the full story. See the LTS:0M8I stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.
58GF Score
Get the complete analysis for LTS:0M8I
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0M8I has been successfully added to your 
